RJA
AST

Raymond James & Associates’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Raymond James & Associates’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,078
Closed -$34K – 3381
2016
Q2 		$34K Buy
+14,078
New +$50.9K ﹤0.01% 2907

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Raymond James & Associates's AST Position: Q3 2016 in Review

Raymond James & Associates sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2016, closing a stake of 14,078 shares — an estimated $34K sold.

Raymond James & Associates first reported a position in AST in Q2 2016 and held it in 1 quarter. The position peaked at $34K in Q2 2016. 64 funds tracked by Wall St. Rank hold AST as of Q3 2016.

  • Raymond James & Associates reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2016 after selling out during the quarter.
  • Raymond James & Associates sold 14,078 Asterias Biotherapeutics Inc. Series A shares in Q3 2016, an estimated $34K.
  • Raymond James & Associates first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 1 quarter.
  • Raymond James & Associates's Asterias Biotherapeutics Inc. Series A position peaked at $34K in Q2 2016.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2016.

Based on Raymond James & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.